07:00 , Jul 15, 2013 |  BC Week In Review  |  Company News

Express Scripts, Symphony Technology deal

Private equity firm Symphony acquired the health economics, health outcomes, market access and retrospective epidemiology and data analytics divisions of Express Scripts' United BioSource Corp. subsidiary. Symphony spun out the acquired divisions into portfolio company...
07:00 , Jul 15, 2013 |  BioCentury  |  Regulation

Coding for utility

New, tougher requirements for obtaining Medicare coverage are increasing the cost and time needed to get laboratory-developed molecular diagnostics onto the market and decreasing the certainty that they will be covered. Empowered by a new...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Company News

Avanir, Express Scripts, VA deal

Avanir, Express Scripts' United BioSource Corp. and the Department of Veterans Affairs announced a pilot study funded by Avanir to screen for pseudobulbar affect (PBA) symptoms in about 1,000 veterans with traumatic brain injury (TBI)....
08:00 , Dec 3, 2012 |  BC Week In Review  |  Company News

Sanofi, Express Scripts deal

Express Scripts' Medco Health Solutions Inc. subsidiary and Sanofi said they have over 60 joint projects underway under a 2011 deal to generate evidence to "demonstrate value of Sanofi products." As part of the deal,...
23:36 , Nov 21, 2012 |  BC Extra  |  Company News

Sanofi, Medco provide update on evidence-based partnership

Medco Health Solutions Inc. and Sanofi (Euronext:SAN; NYSE:SNY) said they have over 60 joint projects underway under a 2011 deal to generate evidence to "demonstrate value of Sanofi products." As part of the deal, pharmacy...
07:00 , Jul 2, 2012 |  BioCentury  |  Politics, Policy & Law

Wake me in November

The Supreme Court's decision last week to leave the Patient Protection and Affordable Care Act largely untouched assures key elements fought for by the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization...
07:00 , Apr 2, 2012 |  BioCentury  |  Politics, Policy & Law

Collateral damage

During oral arguments on the Affordable Care Act at the Supreme Court, attention focused on the constitutionality of the individual mandate to buy health insurance. But for biopharma, what is at stake are provisions that...
08:00 , Jan 30, 2012 |  BioCentury  |  Regulation

AMNOG's uncharted waters

The authors of AMNOG, Germany's new drug pricing law, evidently didn't consider what to do when a drug shows benefit in some patient subgroups but not in others. These drugs, which are rapidly becoming the...
08:00 , Dec 19, 2011 |  BioCentury  |  Regulation

IQWiG spells surprise

InterMune Inc. is counting on Esbriet pirfenidone's Orphan status to protect the idiopathic pulmonary fibrosis drug from a drastic price cut despite a negative review by IQWiG, Germany's health technology assessment agency. The drug is...
07:00 , Sep 19, 2011 |  BioCentury  |  Regulation

Bypassing Germany

The adoption of a comparative efficacy standard as part of Germany's new drug pricing reform law has made it even more difficult to obtain reimbursement above generics prices. As a result, some pharmas already have...